909712-01-2

Basic information

• Product Name: (5-bromopyridin-2-yl)(4-methylpiperazin-1-yl)methanone
• CAS NO: 909712-01-2
• Molecular Weight: 284.156
• Mol File: 909712-01-2.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: (5-bromopyridin-2-yl)(4-methylpiperazin-1-yl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (5-bromopyridin-2-yl)(4-methylpiperazin-1-yl)methanone(909712-01-2)
• EPA Substance Registry System: (5-bromopyridin-2-yl)(4-methylpiperazin-1-yl)methanone(909712-01-2)

Safety Data

• Hazardous Substances Data: 909712-01-2(Hazardous Substances Data)

Usage

Description

(5-bromopyridin-2-yl)(4-methylpiperazin-1-yl)methanone is a chemical compound with the molecular formula C12H15BrN4O, featuring a bromopyridine group and a methylpiperazine group attached to a methanone functional group. (5-bromopyridin-2-yl)(4-methylpiperazin-1-yl)methanone holds potential in medicinal chemistry and drug development due to the presence of these groups, which are known for their various biological activities. The methanone functional group suggests its reactivity and compatibility with different biological systems, making it a valuable building block for synthesizing novel bioactive molecules with potential applications in drug discovery and development.

Uses

Used in Pharmaceutical Industry:
(5-bromopyridin-2-yl)(4-methylpiperazin-1-yl)methanone is used as a building block for the synthesis of novel bioactive molecules due to its versatile chemical structure and potential reactivity with biological systems. The presence of bromopyridine and methylpiperazine groups, which are commonly found in pharmaceuticals, indicates its potential for creating new drugs with various biological activities.
Used in Drug Discovery and Development:
(5-bromopyridin-2-yl)(4-methylpiperazin-1-yl)methanone serves as a key component in the development of new drugs, leveraging its compatibility with different biological systems and the known biological activities of its constituent groups. Its potential applications in medicinal chemistry make it a promising candidate for further research and development in the pharmaceutical field.

Upstream product

• 137178-88-2 5-bromopyridine-2-carbonyl chloride 
• 109-01-3 1-methyl-piperazine 
• 30766-11-1 5-bromoisonicotinic acid 

Relevant articles and documents

Identification of 2-Aminopyrimidine Derivatives as FLT3 Kinase Inhibitors with High Selectivity over c-KIT

Herein, we report two promising compounds 30 and 36 possessing nanomolar FLT3 inhibitory activities (IC50 = 1.5-7.2 nM), high selectivity over c-KIT (>1000-fold), and excellent anti-AML activity (MV4-11 IC50 = 0.8-3.2 nM). Furthermore, these two compounds efficiently inhibited the growth of multiple mutant BaF3 cells expressing FLT3-ITD, FLT3-D835V/F, FLT3-F691L, FLT3-ITD-F691L, and FLT3-ITD-D835Y. Oral administration of 30 and 36 at 6 mg/kg/d could significantly suppress tumor growth in the MV4-11 cell-inoculated xenograft model, exhibiting tumor growth inhibitory rates of 83.5% and 95.1%, respectively. Importantly, 36 could prolong the mouse survival time in the FLT3-ITD-TKD dual mutation syngeneic mouse model (BaF3-FLT3-ITD-D835Y) at a dose of 6 mg/kg p.o. bid/4W. No clear myelosuppression was observed in the treated group of 36 in the MPO strain of zebrafish, even at 10 μM. In summary, our data demonstrated that 36 may represent a promising candidate for the treatment of FLT3 mutant AML.

1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.

Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability

Phosphoinositide 3-kinase (PI3K) is activated in various human cancer cells and well known as a cancer therapy target. We previously reported a dihydropyrrolopyrimidine derivative as a highly potent PI3K inhibitor that has strong tumor growth inhibition in a xenograft model. In this report, we describe further optimization to improve its bioavailability.